AstraZeneca Held Talks With Bristol Myers Squibb on $400 Billion Megadeal

AstraZeneca held talks with Bristol Myers Squibb about a potential “megadeal” valued at roughly $400 billion, according to a report citing people familiar with the matter. The discussions explored combining parts of their businesses, including drug pipelines, manufacturing operations, and commercial reach, as pharma companies look to boost late-stage assets and diversify revenue. Neither company had publicly confirmed the talks, and the report said there is no guarantee negotiations will lead to a transaction. Analysts noted that a deal at this scale would face regulatory scrutiny and shareholder approval hurdles.